Last 42 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -10.71 | — | — | 3.40 | — | — | — | — | — | 1.60 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 66.14 | 67.65 | — | 46.35 | 175.08 | 0.94 | 42.61 | 218.10 | 121.03 | 81.02 | 364.34 | 400.73 | 621.97 | 771.17 | 688.89 | 708.08 | 2918.24 | — | 38.21 | — | — |
| — | +7134.7% | — | -78.7% | +44.7% | -98.8% | -88.3% | -45.6% | -80.5% | -89.5% | -47.1% | -43.4% | -78.7% | — | +1703.1% | — | — | — | +11798.6% | — | — | |
| P/B Ratio | 1.45 | 0.95 | 0.83 | 1.02 | 2.07 | 0.42 | 0.37 | 0.97 | 1.10 | 0.62 | 2.76 | 2.59 | 2.68 | 2.09 | 1.50 | 0.99 | 0.91 | 0.99 | 1.34 | 1.22 | 1.16 |
| — | +124.7% | +120.9% | +4.8% | +88.4% | -31.7% | -86.4% | -62.5% | -59.0% | -70.5% | +83.2% | +161.6% | +193.5% | +110.1% | +12.3% | -18.6% | -21.2% | -22.5% | +10.6% | -64.1% | -78.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 3.45 | — | — | — | — | — | 1.22 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | — | — |
| — | 0.0% | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 0.0% | — | — | — | 0.0% | — | — | |
| Operating Margin | -585.2% | -2141.6% | — | -1712.1% | -9487.1% | -80.9% | -9653.8% | -14107.9% | -7645.1% | -12140.2% | -11768.2% | -12808.5% | -11035.8% | -18896.0% | -22563.6% | -26302.7% | -115329.3% | — | -1125.5% | — | — |
| — | -2547.8% | — | +87.9% | -24.1% | +99.3% | +18.0% | -10.1% | +30.7% | +35.8% | +47.8% | +51.3% | +90.4% | — | -1904.8% | — | — | — | -1428.3% | — | — | |
| Net Margin | -240.1% | -2047.6% | — | 1345.8% | -9210.6% | -74.7% | -7873.1% | -12175.0% | -8096.0% | 5042.0% | -7901.4% | -10790.1% | -10323.9% | -16544.0% | -20236.4% | -24859.1% | -107798.3% | — | -1114.5% | — | — |
| — | -2641.8% | — | +111.1% | -13.8% | -101.5% | +0.4% | -12.8% | +21.6% | +130.5% | +61.0% | +56.6% | +90.4% | — | -1715.8% | — | — | — | -1419.5% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -17.5% | -7.4% | -10.3% | 11.0% | -24.2% | -8.1% | -16.1% | -12.8% | -17.0% | 10.2% | -14.1% | -16.2% | -10.6% | -10.7% | -10.5% | -8.4% | -8.1% | -9.2% | -9.3% | -13.4% | -5.6% |
| — | +9.7% | +35.7% | +186.1% | -42.7% | -179.9% | -14.0% | +21.0% | -59.7% | +195.2% | -33.5% | -93.2% | -30.5% | -16.4% | -12.9% | +37.2% | -44.3% | -24.6% | -107.0% | +67.5% | +83.8% | |
| ROA | -14.3% | -6.6% | -9.0% | 9.0% | -17.2% | -5.9% | -11.8% | -9.5% | -12.7% | 6.8% | -8.5% | -11.4% | -8.6% | -8.9% | -8.9% | -7.2% | -7.0% | -7.9% | -8.4% | -12.5% | -5.4% |
| — | -11.4% | +23.4% | +194.7% | -35.6% | -186.3% | -38.8% | +16.6% | -47.3% | +176.9% | +5.1% | -58.5% | -23.2% | -12.1% | -7.1% | +42.6% | -30.5% | -14.2% | -107.4% | +52.4% | +77.7% | |
| ROIC | -33.9% | -7.4% | -11.3% | -10.9% | -23.7% | -8.1% | -17.2% | -12.1% | -13.1% | -22.2% | -18.7% | -19.9% | -15.6% | -16.4% | -23.7% | -15.2% | -9.8% | -19.6% | -396.8% | — | — |
| — | +8.2% | +34.3% | +9.6% | -81.3% | +63.5% | +7.7% | +39.3% | +16.4% | -35.4% | +21.3% | -30.8% | -58.8% | +16.4% | +94.0% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.06 | 0.01 | 0.10 | 0.31 | 0.25 | 0.24 | 0.22 | 0.20 | 0.18 | 0.20 | 0.18 | 0.16 | 0.15 | 0.14 | 0.13 | 0.11 | 0.10 | 0.10 | — | — |
| — | -76.0% | -97.0% | -52.5% | +55.8% | +37.3% | +21.4% | +18.7% | +22.8% | +24.7% | +47.0% | +45.8% | +40.7% | +40.6% | +41.8% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.91 | 12.39 | 10.17 | 10.91 | 4.24 | 4.72 | 4.93 | 5.32 | 5.66 | 5.73 | 10.47 | 9.55 | 10.59 | 10.07 | 17.78 | 18.79 | 20.87 | 16.94 | 16.63 | 12.87 | 20.37 |
| — | +162.6% | +106.1% | +105.3% | -25.1% | -17.7% | -52.9% | -44.3% | -46.5% | -43.1% | -41.2% | -49.2% | -49.3% | -40.5% | +6.9% | +46.0% | +2.4% | -11.4% | +14.9% | +279.4% | +305.0% | |
| Quick Ratio | 10.91 | 12.39 | 10.17 | 10.91 | 4.24 | 4.72 | 4.93 | 5.32 | 5.66 | 5.73 | 10.47 | 9.55 | 10.59 | 10.07 | 17.78 | 18.79 | 20.87 | 16.94 | 16.63 | 12.87 | 20.37 |
| — | +162.6% | +106.1% | +105.3% | -25.1% | -17.7% | -52.9% | -44.3% | -46.5% | -43.1% | -41.2% | -49.2% | -49.3% | -40.5% | +6.9% | +46.0% | +2.4% | -11.4% | +14.9% | +279.4% | +305.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 42 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OVID stock.
Ovid Therapeutics Inc.'s current P/E is -10.7x. The average P/E over the last 1 quarters is 3.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ovid Therapeutics Inc.'s current operating margin is -585.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ovid Therapeutics Inc.'s business trajectory between earnings reports.